20cm速递丨科创创新药ETF国泰（589720）盘中涨超1.5%，行业新规与创新突破共塑格局

Group 1 - The core viewpoint of the article highlights the recent performance of the pharmaceutical and biotechnology sector, particularly the rise of innovative drugs and the impact of new regulations and breakthroughs in the industry [1] - The innovative drug sector is experiencing active developments, with licensing collaborations expanding from oncology to respiratory, metabolic, and immune fields, including multiple GLP-1 new drug collaborations [1] - The current PE valuation for the pharmaceutical and biotechnology sector stands at 30.88 times, while the chemical pharmaceutical sub-sector has a PE valuation of 36.12 times, indicating a historical median level [1] Group 2 - The Guotai Science and Technology Innovation Drug ETF (589720) has seen an intraday increase of over 1.5%, tracking the Science and Technology Innovation Drug Index (950161), which can fluctuate by up to 20% in a single day [1] - The Science and Technology Innovation Drug Index selects listed companies involved in new drug development and biopharmaceuticals from the STAR Market, reflecting the overall performance of securities related to innovative drug research and development [1] - The index focuses on the cutting-edge areas of China's innovative drug industry, showcasing the high-tech attributes and growth potential of the sector [1]